Navigation Links
ULURU Inc. Announces the Filing of a 510(k) Application for Altrazeal® Collagen
Date:5/4/2011

ADDISON, Texas, May 4, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU) announced today that it has filed a 510(k) application with the U.S. Food and Drug Administration to obtain marketing authorization for Altrazeal® Collagen.

Collagen containing wound care products represent a growing segment of the advanced wound care market. Collagen stimulates cellular migration and contributes to new tissue development. Collagen dressings encourage the deposition and organization of newly formed collagen, creating an environment that fosters healing. Biomaterials with collagen stimulate the wound healing cascade, recruiting specific cells during this process and ultimately, enhance wound healing.

Commenting on the Company's 510(k) application, Kerry P. Gray, President and CEO of ULURU Inc., stated, "Altrazeal® Collagen is an important line extension for our wound care franchise. Initial studies indicate that combining Altrazeal® with collagen provides accelerated wound healing compared to collagen alone, potentially providing additional synergistic benefits. The collagen market segment is a growing and important category within advanced wound care. Having Altrazeal® Collagen available will enable our sales representatives to provide an additional alternative therapy to the wound care professional to treat chronic wounds."

Mr. Gray continued, "The expansion of the Altrazeal® product line to include a collagen product and a silver containing product is an important component of our wound care strategy. Having this full compliment of products will enable us to more effectively compete in the major wound care market segments. Altrazeal® Collagen further enhances the value of the Company's Altrazeal® franchise and makes this asset more attractive to potential strategic partners."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended including our belief that wound care products containing collagen represent a growing market, our belief that Altrazeal® Collagen accelerates wound healing, and our ability to compete in the wound care market. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 Research and Markets has announced the addition ... report to their offering. ... The report also analyses the market by the following Technology Types: ... for the US, Canada , Japan ... Latin America , and Rest of World. ...
(Date:12/9/2016)... 9, 2016 aTyr Pharma, Inc. (Nasdaq: LIFE ... Physiocrine-based therapeutics to address severe, rare diseases, today announced that senior ... Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel in ... 2016, at 4:20 p.m. ET. About aTyr Pharma ... aTyr Pharma ...
(Date:12/9/2016)... 2016  Forge Therapeutics, Inc. today announced a ... EVT, TecDAX, ISIN: DE0005664809) to advance its novel ... of bacterial infections including those caused by drug ... attractive antibacterial target for more than the past ... starting points has hampered its progress. Forge has ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company ... outserts. As a means of expanding capabilities Flottman has added a G&K ... individually code professional inserts (PIs) and patient package inserts (PPIs) that will marry ...
(Date:12/9/2016)... Hills, CA (PRWEB) , ... December 09, 2016 ... ... for young adults, celebrated its 10th anniversary with the grand opening of the ... California. The successful event spanned two days, December 2-3, and was attended by ...
(Date:12/9/2016)... Fort Lee, NJ (PRWEB) , ... December 09, ... ... the 2016 Founders Ball at The Pierre Hotel in New York, NY, on ... 700 friends, benefactors, dignitaries and physicians attended the annual event, which raised over ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... ... December 08, 2016 , ... After ... officially opened registration today for its 33rd Annual Issues & Research Conference, ... , The theme of the conference is “Persistent Challenges and New Opportunities: Using ...
Breaking Medicine News(10 mins):